Drug safety
Bristol Myers reports fatal liver injury in pulmonary fibrosis trial
Bristol Myers said it is unclear whether the patient who died received admilparant or placebo.

Bristol Myers Squibb reported liver-related safety events, including one patient death, in its phase 3 trial of the pulmonary fibrosis drug admilparant. The company does not know whether the patient received admilparant or placebo because the trial remains blinded.
A May amendment for European Union trial sites classified liver injury as a newly important potential risk and called for closer monitoring of participants with abnormally high liver enzyme levels. The amendment said most events were mild, transient, or showed patterns consistent with hepatic adaptation. The fatality followed multi-organ failure, including liver damage, according to BioPharma Dive. Analysts quoted by Fierce Biotech and BioPharma Dive said the reports do not establish whether the death was caused by the drug or point to a risk across the LPA1 drug class.


